Pirfenidone: a novel antifibrotic agent with implications for the treatment of obliterative bronchiolitis.
Dosanjh
A K
AK
Stanford University Medical Center, California, USA.
Wan
B
B
Throndset
W
W
Sherwood
S
S
Morris
R E
RE
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology* / Q000627:therapeutic use; D001980:Bronchi / Q000166:cytology*; D001989:Bronchiolitis Obliterans / Q000188:drug therapy*; D002455:Cell Division / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects; D005434:Flow Cytometry; D006801:Humans; D008168:Lung / Q000166:cytology*; D011728:Pyridones / Q000494:pharmacology* / Q000627:therapeutic use
D000894:Anti-Inflammatory Agents, Non-Steroidal; D011728:Pyridones; C093844:pirfenidone